TrialAnnals of the rheumatic diseases2003

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

L B A van de Putte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.